posted by mike kraft
on Thu, 2022-09-15 19:34
...
The virus has since evolved, and mounting evidence from lab tests suggests the two therapies - sotrovimab as well as casirivimab-imdevimab - have limited clinical activity against the latest iterations of the virus. As a result, they have also fallen out of favour with the U.S. health regulator.
...
Country / Region Tags:
General Topic Tags:
Problem, Solution, SitRep, or ?:
Groups this Group Post belongs to:
- Private group -
